Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews

Bulletin of Faculty of Pharmacy, Cairo University Pub Date : 2017-06-01 DOI:10.1016/j.bfopcu.2016.12.003

Nida Akhtar , Anurag Verma , Kamla Pathak

{"title":"Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews","authors":"Nida Akhtar , Anurag Verma , Kamla Pathak","doi":"10.1016/j.bfopcu.2016.12.003","DOIUrl":null,"url":null,"abstract":"<div><p>Atopic dermatitis (AD) is the most prevalent chronic disease that affects the skin and is featured by inflammation of the skin. Treatment of AD is entirely focused on to limit the itching, skin repairing as well as reducing the inflammation whenever required. A number of therapeutic agents are available for the treatment of AD. However, topical delivery to the skin has been a consistent challenge for researchers, because of the barrier nature of skin. The present review explores the novel nano-sized formulations of various actives researched for AD therapy via topical route. Feasibility of various nano-carrier systems such as elastic vesicles, nanoemulsions, lipid nanoparticles, polymeric micelles and dendritic nanoparticles has been elaborated. The write up traces the pre-clinical and clinical aspects of the nano-formulations. Nano-formulations are found to be an emerging modality for the treatment of AD as they offer targeted delivery, better penetration, enhanced therapeutic efficacy and decreased systemic side effects.</p></div>","PeriodicalId":9369,"journal":{"name":"Bulletin of Faculty of Pharmacy, Cairo University","volume":"55 1","pages":"Pages 1-10"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bfopcu.2016.12.003","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Faculty of Pharmacy, Cairo University","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1110093116300539","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 27

Abstract

Atopic dermatitis (AD) is the most prevalent chronic disease that affects the skin and is featured by inflammation of the skin. Treatment of AD is entirely focused on to limit the itching, skin repairing as well as reducing the inflammation whenever required. A number of therapeutic agents are available for the treatment of AD. However, topical delivery to the skin has been a consistent challenge for researchers, because of the barrier nature of skin. The present review explores the novel nano-sized formulations of various actives researched for AD therapy via topical route. Feasibility of various nano-carrier systems such as elastic vesicles, nanoemulsions, lipid nanoparticles, polymeric micelles and dendritic nanoparticles has been elaborated. The write up traces the pre-clinical and clinical aspects of the nano-formulations. Nano-formulations are found to be an emerging modality for the treatment of AD as they offer targeted delivery, better penetration, enhanced therapeutic efficacy and decreased systemic side effects.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索纳米制剂治疗特应性皮炎的临床前和临床有效性:安全性和专利审查

特应性皮炎(AD)是影响皮肤的最常见的慢性疾病，以皮肤炎症为特征。阿尔茨海默病的治疗完全集中在限制瘙痒，皮肤修复以及减少炎症。许多治疗药物可用于治疗阿尔茨海默病。然而，由于皮肤的屏障特性，局部给药对研究人员来说一直是一个挑战。本文综述了通过局部途径研究的用于阿尔茨海默病治疗的各种活性物质的新型纳米制剂。阐述了各种纳米载体体系的可行性，如弹性囊泡、纳米乳液、脂质纳米粒子、聚合物胶束和树突纳米粒子。这篇文章追溯了纳米制剂的临床前和临床方面。纳米制剂被认为是治疗AD的一种新兴方式，因为它们具有靶向递送、更好的穿透性、更高的治疗效果和更少的全身副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Bulletin of Faculty of Pharmacy, Cairo University

自引率

0.00%

发文量